Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Slides:



Advertisements
Similar presentations
FREEDOMS II TRIAL.
Advertisements

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Multiple sclerosis: Oral Therapies and Beyond
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
New Horizons for SMA.
Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.
Systemic Lupus Erythematosus
Highlights From the 2017 Annual European MS Meeting
MS Highlights From the 2017 Annual Neurology Meeting
Updates on Emerging GLP-1 Receptor Agonists
Progression After Cancer Immunotherapy in Advanced NSCLC
Immune Reconstitution in MS:
Nat. Rev. Neurol. doi: /nrneurol
Current Controversies in Multiple Sclerosis Management
Migraine Prevention Therapy: Avoiding Overuse of Medications
Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Please consider these data to be preliminary until they have been published in peer-reviewed journals.
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Examining CV Effects of Basal Insulin Therapy
New Treatments for CTEPH
Challenges in Managing Progressive Multiple Sclerosis
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Novel Therapies for the Treatment of MS
Next-Gen Psoriasis Therapies:
Evaluating Next-Generation BTK Inhibitors
Hyperhidrosis Is Burdensome!
Immunotherapy for cSCC
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Getting to Grips With the Science of CGRP and Migraine
Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.
Pediatric Multiple Sclerosis: The Dawn of a New Era?
Clinical Pearls on Hot Topics in MS
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
FLT3 Inhibitors in AML.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Wearing Off in Parkinson Disease: The Value of New Generation COMT Inhibition.
Real-World Evidence: What Is It and Why Is It so Important In MS?
Why Opioid Withdrawal Syndrome Should Be on Your Radar
Reducing Risk for CV Outcomes
Novel Concepts in the Management of RCC
Emerging Multiple Sclerosis Therapies
Peanut Allergy Immunotherapy
From Adjuvant to Metastatic in Melanoma
Peanut Allergy Immunotherapy
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Peanut Allergy Immunotherapy
Addressing Cardiovascular Events:
Updates in SMA From an International Muscle Meeting
Pathophysiologic Targets of Allergic Asthma
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
MS, Age, and Immune Function
Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.
The Glutamate Pathway.
Updates in Progressive MS
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.
Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions
Updates on Sickle Cell Disease
Immune Checkpoint Inhibitors in Lung Cancer
Comparative Studies of Biologics in Ulcerative Colitis
A New Era in Migraine Prevention
Understanding the Role of Disability in MS Management
The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?
Presentation transcript:

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Multiple Sclerosis: Clinical Subtypes

Progressive Disease: Overlapping Subtypes?

Radiologically Isolated Syndrome and Risk of MS

Proportion of Patients With SPMS and Other MS Phenotypes

Need to Detect Disease Activity and Disease Progression: Criteria for Progressive MS Phenotypes

Diagnosing SPMS: Input From Patients

Age of Onset of SPMS

Two Components of SMPS as Targets for Treatment

Long-Term Follow-Up on DMT Use: Conversion to SPMS

Recent RCTs in SPMS: Negative for Primary Endpoints

Recent RCTs in SPMS: Positive for Primary Endpoints

Understanding the Pathophysiology of Progressive MS: Potential Treatment Targets

Phase 3 Study of Siponimod: Reduced Risk of Disability Progression

Subgroup Analyses of Phase 3 Study of Siponimod: Risk of Disability Progression at 6 Months

Siponimod in SPMS Shows Distinct Results From Fingolimod in PPMS

S1P Receptor Gene Expression

Randomized, Double-Blind, Placebo-Controlled Study of Biotin in PPMS and SPMS

Extension Phase Results With Biotin: Improvement After Switch From Placebo

Phase 2 Results for High-Dose Simvastatin and Brain Atrophy Reduction in SPMS: MS-STAT

Effect of High-Dose Simvastatin on Cognitive Measures: MS-STAT Cognitive Substudy

Analysis of the Potential Effect of Lipid-Lowering on Disability Reduction With Simvastatin

Phase 2 Study of Ibudilast in PPMS and SPMS

Main Safety Findings With Ibudilast

Ibudilast: Background and Mechanism of Action

MS-SMART: Multiarm Trial Design

PPMS and SPMS as One Entity in Clinical Trials? Clinician Perspectives

Concluding Remarks I

Concluding Remarks II

Abbreviations

Abbreviations (cont)